肠道菌群调节在非酒精性脂肪性肝病中西医治疗中的研究进展

徐萌; 孙凤霞; 李杰; 李晓玲

doi:10.3969/j.issn.1001-5256.2020.06.041

肠道菌群调节在非酒精性脂肪性肝病中西医治疗中的研究进展

DOI: 10.3969/j.issn.1001-5256.2020.06.041

1. 北京中医药大学研究生院
2. 首都医科大学附属北京中医医院感染科

基金项目:

北京市属医院科研培育计划项目(PZ2019011)；北京中医医院院级课题暨两院合作课题(LY201718)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 717
- HTML全文浏览量: 48
- PDF下载量: 152
- 被引次数: 0
出版历程
- 收稿日期: 2020-01-15
- 出版日期: 2020-06-20

Research advances in the role of intestinal flora regulation in the traditional Chinese and Western medicine therapy for nonalcoholic fatty liver disease

Graduate School of Beijing University of Chinese Medicine
Department of Infectious Diseases,Beijing Hospital of Traditional Chinese Medicine,Capital Medical University

Research funding:

摘要

摘要:
目前研究发现,肠道微生物可以在非酒精性脂肪性肝病(NAFLD)治疗中发挥作用,肠道菌群调节将为NAFLD的治疗提供新思路。综述了肠道菌群调节在NAFLD中西医治疗中的研究进展,探究益生菌、粪便菌群移植、抗生素及中药治疗对于调节肠道菌群和改善NAFLD方面的研究现状,为临床提供依据。
- 非酒精性脂肪性肝病 /
- 胃肠道微生物组 /
- 中西医结合疗法
Abstract:
Recent studies have shown that intestinal flora can play a role in the treatment of nonalcoholic fatty liver disease( NAFLD),and intestinal flora regulation can provide new thoughts for the treatment of NAFLD. This article reviews the research advances in the role of intestinal flora regulation in traditional Chinese and Western medicine therapy for NAFLD and explores the current situation of probiotics,fecal flora transplantation,antibiotics,and traditional Chinese medicine therapy in regulating intestinal flora and improving NAFLD,so as to provide a basis for clinical practice.
- nonalcoholic fatty liver disease /
- gastrointestinal microbiome /
- TCM WM therapy

HTML全文

参考文献(44)

[1] National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association;Fatty Liver Expert Committee,Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol,2018,34(5):947-957.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018,34(5):947-957.

[2] QUAN M,XING HC. Research progress on intestinal flora and chronic liver diseases[J/CD]. Chin J Liver Dis(Electr Version),2019,11(3):26-30.(in Chinese)全敏，邢卉春．肠道菌群与慢性肝病相关研究进展[J/CD]．中国肝脏病杂志(电子版)，2019,11(3):26-30.

[3] LU X,HAN T,TIAN Y,et al. Research progress in roles of gut microbiota and bile acid metabolism in development and progression of NAFLD[J]. J Clin Hepatol,2014,30(11):1225-1228.(in Chinese)鲁旭，韩涛，田垚，等．肠道菌群和胆汁酸代谢对非酒精性脂肪性肝病发生发展的作用[J]．临床肝胆病杂志，2014,30(11):1225-1228.

[4] YUAN K,LIN N,CHEN H. The relationship between intestinal flora and the pathogenesis of obesity[J]. Med Recapitulate,2018,24(21):4166-4171.(in Chinese)袁坤，林涅，陈宏．肠道菌群与肥胖发病机制的关系[J]．医学综述，2018,24(21):4166-4171.

[5] WU GL,YU GY,LU WW. Discussion on the TCM essence of intestinal microecology[J]. Chin Arch Tradit Chin Med,2015,33(11):2586-2588.(in Chinese)吴国琳，余国友，卢雯雯．肠道微生态的中医本质探讨[J]．中华中医药学刊，2015,33(11):2586-2588.

[6] QUAN M,XING HC. Progress on Lactobacillus and liver diseases[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition),2019,13(6):467-471.(in Chinese)全敏，邢卉春．乳酸杆菌与肝病研究进展[J/CD]．中华实验和临床感染病杂志(电子版)，2019,13(6):467-471.

[7] GAO B,JEONG WI,TIAN Z. Liver:An organ with predominant innate immunity[J]. Hepatology,2008,47(2):729-736.

[8] ZHANG ZL,DUAN ZJ. Enterohepatic axis-an important goal in the prevention and treatment of liver disease[J]. World Chin J Dig,2016,24(23):3454-3460.(in Chinese)张真玲，段志军．肠肝轴-肝病防治中的重要目标[J]．世界华人消化杂志，2016,24(23):3454-3460.

[9] LI YN,LIANG DW,GAO W. Analysis on the regulating effect of Zhongmanfenxiao Pill on NAFLD from the point of view of intestine-liver axis[J]. Hunan J Tradit Chin Med,2019,35(8):107-108.(in Chinese)李亚楠，梁得稳，高望．从肠-肝轴角度浅析中满分消丸对NAFLD的调节作用[J]．湖南中医杂志，2019,35(8):107-108.

[10] SAFARI Z,GRARD P. The links between the gut microbiome and non-alcoholic fatty liver disease(NAFLD)[J]. Cell Mol Life Sci,2019,76(8):1541-1558.

[11] ZHANG F,ZHANG CH. Dietary nutrition and intestinal microflora[J]. Chin Bull Life Sci,2017,29(7):695-706.(in Chinese)张烽，张晨虹．膳食营养与肠道微生物组[J]．生命科学，2017,29(7):695-706.

[12] LEUNG C,RIVERA L,FURNESS JB,et al. The role of the gut microbiota in NAFLD[J]. Nat Rev Gastroenterol Hepatol,2016,13(7):412-425.

[13] BRSSOW H,PARKINSON SJ. You are what you eat[J]. Nat Biotechnol,2014,32(3):243-245.

[14] BAKER SS,BAKER RD,LIU W,et al. Role of alcohol metabolism in non-alcoholic steatohepatitis[J]. PLo S One,2010,5(3):e9570.

[15] FENG YL,SHANG YS. Research progress on biological function and antioxidant stress of choline[J]. China Feed,2017,13:7-12.(in Chinese)冯宇隆，尚以顺．胆碱的生物学功能及其抗氧化应激的研究进展[J]．中国饲料，2017,13:7-12.

[16] ZHAO JH,MAO XR. The mechanism of intestinal flora in the pathogenesis and treatment of non-alcoholic fatty liver disease[J]. J Lanzhou Univ(Med Sci),2019,45(5):79-85.(in Chinese)赵金花，毛小荣．肠道菌群在非酒精性脂肪性肝病的发病和治疗中的作用机制[J]．兰州大学学报(医学版)，2019,45(5):79-85.

[17] LIU Q,LIU S,CHEN L,et al. Role and effective therapeutic target of gut microbiota in NAFLD/NASH[J]. Exp Ther Med,2019,18(3):1935-1944.

[18] LING L,WANG J,DAN G. Observation on the efficacy of probiotics combined with ursodeoxycholic acid in the treatment of non-alcoholic fatty liver disease[J]. Lab Med Clin,2019,16(23):3413-3415,3420.(in Chinese)凌琳，王俊，但果．益生菌联合熊去氧胆酸治疗非酒精性脂肪性肝病疗效观察[J]．检验医学与临床，2019,16(23):3413-3415,3420.

[19] PAOLELLA G,MANDATO C,PIERRI L,et al. Gut-liver axis and probiotics:Their role in non-alcoholic fatty liver disease[J]. World J Gastroenterol,2014,20(42):15518-15531.

[20] SHI X,CAO YZ,DING YS,et al. The role of intestinal microorganisms in chronic liver disease and its potential therapeutic strategies[J]. Chin Pharmacol Bull,2020,1:18-21.(in Chinese)时行，曹玉珠，丁语石，等．肠道微生物在慢性肝病中的作用及其潜在治疗策略[J]．中国药理学通报，2020,1:18-21.

[21] ALISI A,BEDOGNI G,BAVIERA G,et al. Randomised clinical trial:The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther,2014,39(11):1276-1285.

[22] TEMPLE JL,CORDERO P,LI J,et al. A guide to non-alcoholic fatty liver disease in childhood and adolescence[J]. Int J Mol Sci,2016,17(6):e947.

[23] WANG LJ,ZHANG JP,CHEN MH. Effects of probiotics on liver function glucose and lipid metabolism and intestinal flora in children with non-alcoholic fatty liver[J]. J Chin School Health,2019,40(10):1545-1548.(in Chinese)汪玲娟，张建萍，陈慕恒．益生菌对非酒精性脂肪肝患儿肝功能糖脂代谢及肠道菌群的影响[J]．中国学校卫生，2019,40(10):1545-1548.

[24] WIEST R,ALBILLOS A,TRAUNER M,et al. Targeting the gutliver axis in liver disease[J]. J Hepatol,2017,67(5):1084-1103.

[25] CHO MS,KIM SY,SUK KT,et al. Modulation of gut microbiome in nonalcoholic fatty liver disease:Pro-,pre-,syn-,and antibiotics[J]. J Microbiol,2018,56(12):855-867.

[26] GANGARAPU V,INCE AT,BAYSAL B,et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease[J]. Eur J Gastroenterol Hepatol,2015,27(7):840-845.

[27] YANG L,LIU B,ZHENG J,et al. Rifaximin alters intestinal microbiota and prevents progression of ankylosing spondylitis in mice[J]. Front Cell Infect Microbiol,2019,9:44.

[28] GONZALEZ FJ,JIANG C,PATTERSON AD. An intestinal microbiota-farnesoid X receptor axis modulates metabolic Disease[J]. Gastroenterology,2016,151(5):845-859.

[29] LI YQ. Protective effect of fecal bacteria transplantation on liver and intestinal mucosal barrier in rats with non-alcoholic fatty liver disease[D]. Shijiazhuang:Hebei Medical University,2016.(in Chinese)李月芹．粪菌移植对非酒精性脂肪性肝病大鼠肝脏及肠黏膜屏障保护作用的研究[D]．石家庄:河北医科大学，2016.

[30] NOBILI V,MOSCA A,ALTERIO T,et al. Fighting fatty liver diseases with nutritional interventions,probiotics,symbiotics,and fecal microbiota transplantation(FMT)[J]. Adv Exp Med Biol,2019,1125:85-100.

[31] ZHOU D,PAN Q,SHEN F,et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep,2017,7(1):1529.

[32] PHILIPS CA,PANDE A,SHASTHRY SM,et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis:A pilot study[J]. Clin Gastroenterol Hepatol,2017,15(4):600-602.

[33] ZHANG LL,HU JH. Effect of traditional Chinese medicine on intestinal microecology of chronic liver disease[J]. Beijing J Tradit Chin Med,2019,38(3):226-229.(in Chinese)张丽丽，胡建华．中医药对慢性肝病肠道微生态的影响研究现状[J]．北京中医药，2019,38(3):226-229.

[34] YU X,WANG WJ,JIN JY,et al. Linggui Zhugan decoction combined with probiotics in the treatment of nonalcoholic fatty liver disease[J]. J Changchun Univ Chin Med,2019,35(5):891-894.(in Chinese)喻晓，王雯婕，金嘉悦，等．苓桂术甘汤联合益生菌治疗非酒精性脂肪肝[J]．长春中医药大学学报，2019,35(5):891-894.

[35] JIANG DJ,ZHANG L,CAO YD,et al. Application of intestinal flora in the study of traditional Chinese medicine[J]. China J Chin Mater Med,2016,41(17):3218-3225.(in Chinese)姜东京，张丽，曹雨诞，等．肠道菌群在中药研究中的应用[J]．中国中药杂志，2016,41(17):3218-3225.

[36] LI BL,WANG JJ,DUAN TT,et al. Research progress of traditional Chinese medicine in the prevention and treatment of non-alcoholic fatty liver based on intestinal flora regulation[J].Med Recapitulate,2019,25(21):4281-4285.(in Chinese)李宝龙，王娇娇，段婷婷，等．基于肠道菌群调节的中医药防治非酒精性脂肪肝的研究进展[J]．医学综述，2019,25(21):4281-4285.

[37] TIAN HJ,FENG Q,HU YY. Role of gut microbiota regulation in traditional Chinese medicine treatment of non-alcoholic fatty liver disease[J]. J Clin Hepatol,2015,31(7):1042-1045.(in Chinese)田华捷，冯琴，胡义扬．调节肠道菌群在中医药治疗非酒精性脂肪性肝病中的作用和意义[J]．临床肝胆病杂志，2015,31(7):1042-1045.

[38] WANG LL,GUO HH,HUANG S,et al. Comprehensive evaluation of SCFA production in the intestinal bacteria regulated by berberine using gas-chromatography combined with polymerase chain reaction[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2017,1057:70-80.

[39] QIAO Y,SUN J,XIA S,et al. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity[J]. Food Funct,2014,5(6):1241-1249.

[40] CHEN X,CHAN H,ZHANG L,et al. The phytochemical polydatin ameliorates non-alcoholic steatohepatitis by restoring lysosomal function and autophagic flux[J]. J Cell Mol Med,2019,23(6):4290-4300.

[41] SEO DB,JEONG HW,CHO D,et al. Fermented green tea extract alleviates obesity and related complications and alters gut microbiota composition in diet-induced obese mice[J].J Med Food,2015,18(5):549-556.

[42] ZHU Q,WANG XG,WANG Q,et al. Effect of Xiaozhi decoction on intestinal microflora of mice with non-alcoholic steatohepatitis[J]. Chin J Exp Med Formul,2017,23(14):164-170.(in Chinese)朱青，王晓歌，王奇，等．消脂汤对非酒精性脂肪性肝炎小鼠肠道主要菌群的影响[J]．中国实验方剂学杂志，2017,23(14):164-170.

[43] XU L,FU J,FANG F,et al. Efficacy of modified Yin Chenwuling Powder in the treatment of damp-heat accumulation type of non-alcoholic fatty liver disease and its effect on intestinal flora[J]. Chin J Exp Med Formul,2019,25(12):127-132.(in Chinese)徐立，符晶，方芳，等．加味茵陈五苓散治疗湿热蕴结型非酒精性脂肪性肝病的疗效及对肠道菌群的影响[J]．中国实验方剂学杂志，2019,25(12):127-132.

[44] SUN T,CHEN XM,LIU YC. Clinical observation of Jiawei Tiaozhi recipe combined with bifid triple viable bacteria in the treatment of non-alcoholic fatty liver disease[J]. Chin J Integr Trad West Med Dig,2018,26(6):472-477.(in Chinese)孙涛，陈小梅，刘英超．加味调脂方联合双歧三联活菌治疗非酒精性脂肪性肝病的临床疗效观察[J]．中国中西医结合消化杂志，2018,26(6):472-477.

施引文献

资源附件(0)

访问统计